The Scientific Committee:

Eric Van Cutsem  ESDO President, BGDO past president  Belgium
Ivan Borbath  BGDO President  Belgium
Thomas Seufferlein  ESDO Secretary General  Germany
Jean-Luc Van Laethem  ESDO Education Committee, BGDO board  Belgium

Faculty:

Regina Beets-Tan  Netherlands
Ivan Borbath  Belgium
Pierre Coulie  Belgium
Christophe De Roose  Belgium
Elleke Dresen  Belgium
Karen Geboes  Belgium
Ulrich Gueller  Switzerland
Aline Hebrant  Belgium
Alain Hendlisz  Belgium
Côme Lepage  France
Murielle Mauer  Belgium
Markus Moehler  Germany
Patrick Pauwels  Belgium
Marc Peeters  Belgium
Wolff Schmiegel  Germany
Max Seidensticker  Germany
Magali Svrcek  France
Julien Taieb  France
Eric Van Cutsem  Belgium
Jean-Luc Van Laethem  Belgium
FRIDAY  6 October 2017

09:00  Advances in Immuno-Oncology in GI Cancer

Chairs: Thomas Seufferlein, Ulm and Eric Van Cutsem, Leuven

- Understanding immune mechanisms in cancer and how to interfere?
  - Basic mechanisms  Pierre Coulie, Brussels
  - Clinical mechanisms of action  Markus Moehler, Mainz
- Clinical trials in GI cancer  Julien Taieb, Paris
- Design and interpretation of trials:  hurdles, requirements and conditions  (round table discussion)

11:15  BREAK

11:30  Statistics for the Clinicians

Chairs: Marc Peeters, Antwerp and Côme Lepage, Dijon

- General principles  Ulrich Gueller, St. Gallen
- Innovative design of trials in the era of targeted agents  Murielle Mauer, EORTC – Brussels

13:00  LUNCH

14:00  Clinical Relevance of New Targets and of Molecular Taxonomy in GI Cancer

Chairs: Wolf Schmiegel, Bochum and Karen Geboes, Gent

- Gastric cancer: new targeted agents  Eric Van Cutsem, Leuven
- Pancreatic cancer:
  - molecular classification  Jean-Luc Van Laethem, Brussels
  - how do we progress with new agents in the clinic?  Thomas Seufferlein, Ulm
- Molecular alterations in hepatocellular carcinoma:
  from malignant transformation to therapeutic targets  Ivan Borbath, Brussels

16:00  BREAK

16:15  Technology platforms for Molecular Drugs: how to apply this in clinical practice

Chairs: Thomas Seufferlein, Ulm and Patrick Pauwels, Antwerp

- Technology Platforms for Molecular Drugs:  Aline Hebrant, WIV- Belgian Cancer Centre, Brussels
PROGRAMME: INNOVATION IN GI CANCERS

- Liquid biopsies  
  Wolff Schmiegel, Bochum
- New insights in MSI testing:  
  from a pathologist's point of view  
  Magali Svrcek, Paris

17:30  END of DAY 1

SATURDAY  7 October 2017

09:00  Functional imaging in GI cancer

Chairs: Alain Hendlisz, Brussels and Ulrich Gueller, St. Gallen
- The role of MRI in response evaluation  
  Elleke Dresen, Leuven
- Optimizing MRI in rectal cancer  
  Regina Beets-Tan, Amsterdam
- Response evaluation after loco-regional therapy  
  Max Seidensticker, Magdeburg
- The role of PET/CT in functional evaluation  
  Christophe Deroose, Leuven

11:15  BREAK

11:45  Innovation and Clinical practise

Chairs: Eric Van Cutsem, Leuven and Ivan Borbath, Brussels
- The impact of epidemiologic studies in GI cancer  
  Côme Lepage, Dijon
- Molecular Tumor Board: Clinical case discussion  
  Panel: TBC
- Conclusion: Future innovations in GI Cancer  
  Eric Van Cutsem & Thomas Seufferlein

13:00  END

SUPPORTING PARTNERS

ESDO European Society of Digestive Oncology  c/o Vienna Medical Academy
1090 Vienna  |  Alser Strasse 4  |  t +43.1.4051383.38  |  f +43.1.4078274  |  www.esdo.eu